Ex-Eylea Leader Launches Biotech Targeting Untapped Eye Market
Complement Therapeutics Exits Stealth Mode
Former Bayer executive Rafiq Hasan believes the start-up’s gene therapy candidate can open up treatment to millions of patients with dry AMD and geographic atrophy.
